摘要:
The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
摘要:
The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.
摘要:
The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
摘要:
The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.
摘要:
The invention relates medicaments comprising novel polyethylene glycol (PEG) based prodrugs of Adrenomedullin, or one of the salts thereof, solvates thereof or the solvates of salts thereof, in combination with an inert nontoxic pharmaceutically suitable excipient, wherein the medicament is in a pharmaceutical form for inhalation, its use for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, to specific PEG-adrenomedullin prodrugs and its synthesis intermediates.